David Sinclair’s firm Life Biosciences recently launched a first-of-its-kind in vivo reprogramming trial called ER-100. I wrote about how the odds were against this trial succeeding but hoped I was wrong to be skeptical. The idea is to use a pulse of OCT4, SOX2, and KLF4 (OSK) to try to somehow help visual issues including […]
The post Weekly reads: ER-100 trial update, ND AG stem cell alert, autoimmune CAR-T hurdles, AI effects on biologists, No on Prop 38 appeared first on The Niche.